News

Treatment with subcutaneous interferon beta-1a plus remdesivir was not superior to treatment with remdesivir alone in a clinical trial that enrolled 969 hospitalized adults with COVID-19 pneumonia in the United States, Japan, Mexico, Singapore and South Korea, the National Institutes of Health reported.

The Health Resources and Services Administration Oct. 21 will host the last in a series of webinar sessions on how to apply for a portion of $25.5 billion in COVID-19 relief funds.

Two doses of the Pfizer vaccine are 93% effective at preventing COVID-19 hospitalization among children aged 12 to 18, according to a study at 19 pediatric hospitals released by the Centers for Disease Control and Prevention.

The AHA urged the Centers for Medicare & Medicaid Services to conduct the necessary oversight and enforcement of the No Surprises Act to ensure patients benefit from these new protections and to prevent widespread, negative consequences of any misapplication of the policy.

Nearly three-fourths of the 2.4 million U.S. adults who reported using buprenorphine in 2019 did not misuse the medication in the past 12 months, according to a National Institutes of Health study released in JAMA Network Open.

The Food and Drug Administration approved the first interchangeable biosimilar product for Humira, a monoclonal antibody used to treat certain inflammatory diseases.

A symposium hosted by the AHA at the HLTH conference featured a panel of experts discussing health transformation in the post-pandemic world.

The Agency for Healthcare Research and Quality seeks input through Nov. 12 on scientific evidence to inform a systematic review of telehealth use during COVID-19.

The AHA urged the Centers for Medicare & Medicaid Services to revise and reissue recent proposed regulations streamlining prior authorization requirements within certain coverage programs; consider additional regulations to limit care delays; and conduct oversight and enforcement for plans who have demonstrated problematic prior authorization usage in the past.

The Department of Health and Human Services’ Health Sector Cybersecurity Coordination Center (HC3) issued a monthly bulletin that consolidates a wide range of cyber security alerts from across government on the latest cybersecurity trends and threats, including guidance on hardening remote access virtual private networks. 

The Centers for Disease Control and Prevention updated the list of underlying medical conditions that put adults of any age at higher risk for severe COVID-19 based on the latest scientific evidence.

Working in health care delivery can be stressful and tiring under normal circumstances. And the COVID-19 pandemic has exerted incredible pressures on the emotional and physical well-being of our health care professionals. 

The Department of Health and Human Services has renewed the COVID-19 public health emergency declaration for another 90 days effective Oct. 18.

This year’s AHA Dick Davidson NOVA Award honorees from CommonSpirit Health, Luminis Health, Memorial Health System, Providence, and Texas Health Resources will discuss their award-winning programs to address homelessness, an aging population, behavioral health and substance use, lagging community wellness and the COVID-19 outbreak during an AHA webinar Oct. 26 at 12 p.m. ET.

The National Institutes of Health awarded a total of $78 million in funding to develop and manufacture 12 new rapid diagnostic tests for SARS-CoV-2, with the goal of bringing to market as soon as this year new home and point-of-care tests that can detect multiple respiratory infections.

States and territories can apply through April 8, 2022, for a portion of $100 million in American Rescue Plan Act funding to help repay educational loans for primary care clinicians in exchange for service in underserved communities, the Health Resources and Services Administration announced.

A coalition of hospital and physician organizations, including the AHA, urged the Centers for Medicare & Medicaid Services to give Medicare accountable care organizations the option to use pre-pandemic spending benchmarks to set financial targets beginning in performance year 2022.

Abbott Molecular Inc. issued a recall for its Alinity m SARS-CoV-2 AMP Kits and Alinity m Resp-4-Plex AMP Kits, distributed between May 13, 2020, and Aug. 31, 2021, for their potential to give false positive results.

The Centers for Disease Control and Prevention released an operational planning guide for pediatric COVID-19 vaccination and preliminary information on the pediatric Pfizer COVID-19 vaccine.

Available data support the safety and effectiveness of the Johnson & Johnson COVID-19 vaccine for emergency use authorization as a booster dose in individuals aged 18 and older at least two months after an initial single dose, the Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee voted 19-0.